Cargando…

Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites

BACKGROUND: The alfapump(®) is an implantable class III medical device that pumps ascitic fluid from the peritoneal space to the urinary bladder from where it is excreted. The pump reduces or abrogates the need for repeated paracentesis in patients with recurrent or refractory ascites. AIMS: To impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Aagaard, Niels Kristian, Malago, Massimo, De Gottardi, Andrea, Thomas, Michael, Sauter, Gerd, Engelmann, Cornelius, Aranovich, David, Cohen, Michal, Thévenot, Thierry, Ehmann, Thomas, Capel, Jeroen, Angeli, Paolo, Jalan, Rajiv, Stirnimann, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905806/
https://www.ncbi.nlm.nih.gov/pubmed/35260086
http://dx.doi.org/10.1186/s12876-022-02173-5
_version_ 1784665270355230720
author Aagaard, Niels Kristian
Malago, Massimo
De Gottardi, Andrea
Thomas, Michael
Sauter, Gerd
Engelmann, Cornelius
Aranovich, David
Cohen, Michal
Thévenot, Thierry
Ehmann, Thomas
Capel, Jeroen
Angeli, Paolo
Jalan, Rajiv
Stirnimann, Guido
author_facet Aagaard, Niels Kristian
Malago, Massimo
De Gottardi, Andrea
Thomas, Michael
Sauter, Gerd
Engelmann, Cornelius
Aranovich, David
Cohen, Michal
Thévenot, Thierry
Ehmann, Thomas
Capel, Jeroen
Angeli, Paolo
Jalan, Rajiv
Stirnimann, Guido
author_sort Aagaard, Niels Kristian
collection PubMed
description BACKGROUND: The alfapump(®) is an implantable class III medical device that pumps ascitic fluid from the peritoneal space to the urinary bladder from where it is excreted. The pump reduces or abrogates the need for repeated paracentesis in patients with recurrent or refractory ascites. AIMS: To improve outcomes for alfapump(®) implantation and pre- and post-implant patient management in both clinical trial and real-world settings by development of consensus recommendations. METHODS: The alfapump(®) working group consisting of hepatologists and surgeons with extensive experience in implantation of the alfapump(®) and patient management met on two occasions: (1) to determine the key areas where recommendations should be made; and (2) to discuss the experiences of the working group within those areas and formulate draft statements. Developed statements were submitted to the group and consensus sought on relevance and wording through a collaborative iterative approach in order to consolidate the recommendations into consensus statements. Only recommendations agreed upon unanimously were included. RESULTS: Twenty-three consensus recommendations were developed in the areas of pre-implantation procedure, (three statements), surgical implant procedure (11 statements), immediate post-implant care (three statements) and long-term management (six statements). CONCLUSIONS: The consensus statements are a valuable reference resource for physicians managing patients with the alfapump(®) and for those considering management strategies for patients with refractory ascites. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02173-5.
format Online
Article
Text
id pubmed-8905806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89058062022-03-18 Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites Aagaard, Niels Kristian Malago, Massimo De Gottardi, Andrea Thomas, Michael Sauter, Gerd Engelmann, Cornelius Aranovich, David Cohen, Michal Thévenot, Thierry Ehmann, Thomas Capel, Jeroen Angeli, Paolo Jalan, Rajiv Stirnimann, Guido BMC Gastroenterol Research BACKGROUND: The alfapump(®) is an implantable class III medical device that pumps ascitic fluid from the peritoneal space to the urinary bladder from where it is excreted. The pump reduces or abrogates the need for repeated paracentesis in patients with recurrent or refractory ascites. AIMS: To improve outcomes for alfapump(®) implantation and pre- and post-implant patient management in both clinical trial and real-world settings by development of consensus recommendations. METHODS: The alfapump(®) working group consisting of hepatologists and surgeons with extensive experience in implantation of the alfapump(®) and patient management met on two occasions: (1) to determine the key areas where recommendations should be made; and (2) to discuss the experiences of the working group within those areas and formulate draft statements. Developed statements were submitted to the group and consensus sought on relevance and wording through a collaborative iterative approach in order to consolidate the recommendations into consensus statements. Only recommendations agreed upon unanimously were included. RESULTS: Twenty-three consensus recommendations were developed in the areas of pre-implantation procedure, (three statements), surgical implant procedure (11 statements), immediate post-implant care (three statements) and long-term management (six statements). CONCLUSIONS: The consensus statements are a valuable reference resource for physicians managing patients with the alfapump(®) and for those considering management strategies for patients with refractory ascites. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02173-5. BioMed Central 2022-03-08 /pmc/articles/PMC8905806/ /pubmed/35260086 http://dx.doi.org/10.1186/s12876-022-02173-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Aagaard, Niels Kristian
Malago, Massimo
De Gottardi, Andrea
Thomas, Michael
Sauter, Gerd
Engelmann, Cornelius
Aranovich, David
Cohen, Michal
Thévenot, Thierry
Ehmann, Thomas
Capel, Jeroen
Angeli, Paolo
Jalan, Rajiv
Stirnimann, Guido
Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
title Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
title_full Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
title_fullStr Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
title_full_unstemmed Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
title_short Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
title_sort consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905806/
https://www.ncbi.nlm.nih.gov/pubmed/35260086
http://dx.doi.org/10.1186/s12876-022-02173-5
work_keys_str_mv AT aagaardnielskristian consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT malagomassimo consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT degottardiandrea consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT thomasmichael consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT sautergerd consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT engelmanncornelius consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT aranovichdavid consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT cohenmichal consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT thevenotthierry consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT ehmannthomas consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT capeljeroen consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT angelipaolo consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT jalanrajiv consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites
AT stirnimannguido consensuscarerecommendationsforalfapumpincirrhoticpatientswithrefractoryorrecurrentascites